BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 30402050)

  • 1. Time to Disease Recurrence Is a Predictor of Metastasis and Mortality in Patients with High-risk Prostate Cancer Who Achieved Undetectable Prostate-specific Antigen Following Robot-assisted Radical Prostatectomy.
    Kim DK; Koo KC; Lee KS; Hah YS; Rha KH; Hong SJ; Chung BH
    J Korean Med Sci; 2018 Nov; 33(45):e285. PubMed ID: 30402050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive factors and oncological outcomes of persistently elevated prostate-specific antigen in patients following robot-assisted radical prostatectomy.
    Kumar A; Samavedi S; Mouraviev V; Bates AS; Coelho RF; Rocco B; Patel VR
    J Robot Surg; 2017 Mar; 11(1):37-45. PubMed ID: 27245233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients.
    Abdollah F; Sood A; Sammon JD; Hsu L; Beyer B; Moschini M; Gandaglia G; Rogers CG; Haese A; Montorsi F; Graefen M; Briganti A; Menon M
    Eur Urol; 2015 Sep; 68(3):497-505. PubMed ID: 26119559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small-volume lymph node involvement and biochemical recurrence after robot-assisted radical prostatectomy with extended lymph node dissection in prostate cancer.
    Morizane S; Honda M; Shimizu R; Teraoka S; Nishikawa R; Tsounapi P; Kimura Y; Iwamoto H; Hikita K; Takenaka A
    Int J Clin Oncol; 2020 Jul; 25(7):1398-1404. PubMed ID: 32333202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single Positive Lymph Node Prostate Cancer Can Be Treated Surgically without Recurrence.
    Kim DK; Koo KC; Abdel Raheem A; Kim KH; Chung BH; Choi YD; Rha KH
    PLoS One; 2016; 11(3):e0152391. PubMed ID: 27031340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncologic Outcomes After Robot-assisted Radical Prostatectomy: A Large European Single-centre Cohort with Median 10-Year Follow-up.
    Rajan P; Hagman A; Sooriakumaran P; Nyberg T; Wallerstedt A; Adding C; Akre O; Carlsson S; Hosseini A; Olsson M; Egevad L; Wiklund F; Steineck G; Wiklund NP
    Eur Urol Focus; 2018 Apr; 4(3):351-359. PubMed ID: 28753802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncologic outcomes at 10 years following robotic radical prostatectomy.
    Diaz M; Peabody JO; Kapoor V; Sammon J; Rogers CG; Stricker H; Lane Z; Gupta N; Bhandari M; Menon M
    Eur Urol; 2015 Jun; 67(6):1168-1176. PubMed ID: 24996687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
    Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive factors and the important role of detectable prostate-specific antigen for detection of clinical recurrence and cancer-specific mortality following robot-assisted radical prostatectomy.
    García-Barreras S; Rozet F; Nunes-Silva I; Srougi V; Sanchez-Salas R; Barret E; Galiano M; Cathelineau X
    Clin Transl Oncol; 2018 Aug; 20(8):1004-1010. PubMed ID: 29243074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intermediate-term cancer control outcomes in prostate cancer patients treated with robotic-assisted laparoscopic radical prostatectomy: a multi-institutional analysis.
    Abdollah F; Dalela D; Sood A; Sammon J; Jeong W; Beyer B; Fossati N; Rogers CG; Diaz-Insua M; Peabody J; Haese A; Montorsi F; Graefen M; Briganti A; Menon M
    World J Urol; 2016 Oct; 34(10):1357-66. PubMed ID: 26873596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting pathological outcomes in patients undergoing robot-assisted radical prostatectomy for high-risk prostate cancer: a preoperative nomogram.
    Abdollah F; Klett DE; Sood A; Sammon JD; Pucheril D; Dalela D; Diaz M; Peabody JO; Trinh QD; Menon M
    BJU Int; 2015 Nov; 116(5):703-12. PubMed ID: 25413443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of biochemical recurrence after Retzius-sparing robot-assisted radical prostatectomy: Analysis of 359 cases with a median follow-up period of 26 months.
    Abdel Raheem A; Chang KD; Alenzi MJ; Ham WS; Han WK; Choi YD; Rha KH
    Int J Urol; 2018 Dec; 25(12):1006-1014. PubMed ID: 30276864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting early outcomes in patients with intermediate- and high-risk prostate cancer using prostate-specific membrane antigen positron emission tomography and magnetic resonance imaging.
    Meijer D; van Leeuwen PJ; Donswijk ML; Boellaard TN; Schoots IG; van der Poel HG; Hendrikse HN; Oprea-Lager DE; Vis AN
    BJU Int; 2022 Jan; 129(1):54-62. PubMed ID: 34028165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term cancer control outcomes of robot-assisted radical prostatectomy for prostate cancer treatment: a meta-analysis.
    Wang L; Wang B; Ai Q; Zhang Y; Lv X; Li H; Ma X; Zhang X
    Int Urol Nephrol; 2017 Jun; 49(6):995-1005. PubMed ID: 28238148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical recurrence after robot-assisted extended pelvic lymphadenectomy for prostate cancer.
    Chenam A; Ruel N; Pal S; Barlog J; Lau C; Wilson T; Yuh B
    Can J Urol; 2018 Jun; 25(3):9340-9348. PubMed ID: 29900823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Propensity score comparison of the various radical surgical techniques for high-risk prostate cancer].
    Busch J; Gonzalgo M; Leva N; Ferrari M; Friedersdorff F; Hinz S; Kempkensteffen C; Miller K; Magheli A
    Aktuelle Urol; 2015 Jan; 46(1):45-51. PubMed ID: 25526221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection in Patients with Locally-advanced Prostate Cancer.
    Gandaglia G; De Lorenzis E; Novara G; Fossati N; De Groote R; Dovey Z; Suardi N; Montorsi F; Briganti A; Rocco B; Mottrie A
    Eur Urol; 2017 Feb; 71(2):249-256. PubMed ID: 27209538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.